Galenica (GALE) Q3 2025 TU earnings summary

Executive summary

• Net sales for the first nine months of 2025 increased by 4.7% year-over-year, reaching CHF 2,999.7 million, driven by prescription drugs and dietary supplements.

• Both Products & Care and Logistics & IT segments contributed to growth, each up 5.0% year-over-year.

• The acquisition of Labor Team Group boosted sales and led to an upward revision of full-year guidance.

Financial highlights

• Products & Care segment net sales rose to CHF 1,304.4 million (+5.0%), while Logistics & IT reached CHF 2,479.9 million (+5.0%).

• Retail (B2C) sales grew 4.9% to CHF 1,097.0 million, with Local Pharmacies up 5.1% and Pharmacies at Home up 1.3%.

• Services for Professionals saw strong growth of 15.9%, reaching CHF 72 million, mainly due to the Labor Team acquisition.

• Wholesale sales increased 5.0% to CHF 2,375 million, with notable gains in the physicians segment.

• Logistics & IT Services sales rose 6.4% to CHF 124 million, driven by internal IT services and increased CDS Checks.

Outlook and guidance

• Net sales guidance for 2025 raised to 4–6% growth, reflecting the Labor Team acquisition.

• EBIT guidance adjusted to 10–12% growth, accounting for a CHF 5.4 million one-off effect and the Labor Team acquisition.

• Excluding the acquisition, previous outlook confirmed: net sales growth of 3–5% and EBIT increase of 7–9%.

• Dividend expected to be at least at the previous year's level.